DILH
AERI

Dai-ichi Life Holdings’s Aerie Pharmaceuticals AERI Stock Holding History

Dai-ichi Life Holdings’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-24,286
Closed -$917K – 486
2016
Q3 		$917K Buy
+24,286
New +$536K 0.03% 413

Other funds holding AERI

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dai-ichi Life Holdings's AERI Position: Q4 2016 in Review

Dai-ichi Life Holdings sold out of Aerie Pharmaceuticals (AERI) in Q4 2016, closing a stake of 24,286 shares — an estimated $917K sold.

Dai-ichi Life Holdings first reported a position in AERI in Q3 2016 and held it in 1 quarter. The position peaked at $917K in Q3 2016. 151 funds tracked by Wall St. Rank hold AERI as of Q4 2016.

  • Dai-ichi Life Holdings reported no remaining Aerie Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Dai-ichi Life Holdings sold 24,286 Aerie Pharmaceuticals shares in Q4 2016, an estimated $917K.
  • Dai-ichi Life Holdings first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Dai-ichi Life Holdings's Aerie Pharmaceuticals position peaked at $917K in Q3 2016.
  • 151 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2016.

Based on Dai-ichi Life Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.